Hims & Hers Health Inc’s filing revealed that its Officer Chi Michael acquired Company’s shares for reported $0.29 million on Jun 06 ’25. In the deal valued at $56.00 per share,5,100 shares were bought.
Then, Melissa Baird bought 33,333 shares, generating $1,786,982 in total proceeds.
Before that, Okupe Oluyemi sold 11,581 shares. Hims & Hers Health Inc shares valued at $613,537 were divested by the Chief Financial Officer at a price of $52.98 per share. As a result of the transaction, Okupe Oluyemi now holds 39,153 shares, worth roughly $2.21 million.
Needham reiterated its Hims & Hers Health Inc [HIMS] rating to a Buy in a research note published on June 04, 2025; the price target was $65. A number of analysts have revised their coverage, including TD Cowen’s analysts, who decreased its forecast for the stock in late April from “a Buy” to “a Hold”. Morgan Stanley also remained covering HIMS and has decreased its forecast on February 18, 2025 with a “an Equal-weight” recommendation from previously “an Overweight” rating. Citigroup revised its rating on January 10, 2025. It rated HIMS as “a Sell” which previously was an “a Neutral”.
Price Performance Review of HIMS
On Friday, Hims & Hers Health Inc [NYSE:HIMS] saw its stock jump 6.75% to $56.33. Over the last five days, the stock has lost -0.41%. Hims & Hers Health Inc shares have risen nearly 132.96% since the year began. Nevertheless, the stocks have risen 170.43% over the past one year. While a 52-week high of $72.98 was reached on 02/19/25, a 52-week low of $13.47 was recorded on 04/04/25. SMA at 50 days reached $41.89, while 200 days put it at $31.40.
Levels Of Support And Resistance For HIMS Stock
The 24-hour chart illustrates a support level at 53.55, which if violated will result in even more drops to 50.77. On the upside, there is a resistance level at 58.31. A further resistance level may holdings at 60.29. The Relative Strength Index (RSI) on the 14-day chart is 58.25, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.46, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.27%. Stochastics %K at 18.78% indicates the stock is a buying.
The most recent change occurred on January 07, 2025 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $35 price target.
